%0 Journal Article %A Milind P Sovani %A Christopher I Whale %A Janet Oborne %A Sue Cooper %A Kevin Mortimer %A Tommy Ekström %A Anne E Tattersfield %A Timothy W Harrison %T Poor adherence with inhaled corticosteroids for asthma: can using a single inhaler containing budesonide and formoterol help? %D 2008 %R 10.3399/bjgp08X263802 %J British Journal of General Practice %P 37-43 %V 58 %N 546 %X Background Poor adherence with inhaled corticosteroids is an important problem in asthma management. Previous approaches to improving adherence have had limited success.Aim To determine whether treatment with a single inhaler containing a long-acting β2-agonist and a corticosteroid for maintenance treatment and symptom relief can overcome the problem of poor adherence with inhaled corticosteroids.Design of study Randomised, parallel group, open-label trial.Setting Forty-four general practices in Nottinghamshire.Method Participants who used less than 70% of their prescribed dose of inhaled corticosteroid and had poorly controlled asthma were randomised to budesonide 200 μg one puff twice daily plus their own short-acting β2-agonist as required (control group), or budesonide/formoterol 200/6 μg one puff once daily and as required (active group) for 6 months. The primary outcome was inhaled corticosteroid dose.Results Seventy-one participants (35 control, 36 active group) were randomised. Adherence with budesonide in the control group was approximately 60% of the prescribed dose. Participants in the active group used approximately 80% more budesonide than participants in the control group (448 versus 252 μg/day, mean difference 196 μg, 95% confidence interval 113 to 279; P<0.001) and were less likely to withdraw from the study (3 versus 13; P<0.01). No safety issues were identified.Conclusion Using a single inhaler for both maintenance treatment and symptom relief approximately doubled the dose of inhaled corticosteroid taken, suggesting this could be a useful strategy to overcome the problems related to poor adherence with inhaled corticosteroids. %U https://bjgp.org/content/bjgp/58/546/37.full.pdf